Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test for TB Could Eliminate Unnecessary Treatment

By LabMedica International staff writers
Posted on 25 Jun 2014
A new screening process for tuberculosis (TB) infections in Canadian prisons could mean that more than 50% of those screened will not undergo unnecessary treatment due to false positives.

A test for TB using interferon-gamma release assays (IGRA) will detect a preexisting TB infection, or latent TB, that might not present itself for many years, or until the body becomes weakened by another source. More...


A study group led by infectious disease experts from Queen’s University (Kingston, ON, Canada), tested inmates for TB at a Canadian intake institution before moving on to different corrections facilities. The scientists used both the tuberculosis skin test (TST) for TB which has been used for over 100 years but comes with two main limitations, and the IGRA. The TST requires two visits to determine the results: one to perform the test and then another visit a couple of days later to read the results and depending on the patient's exposure to other mycobacteria or the Bacille Calmette Guerin (BCG) vaccine, accordingly the TST test can give many false positives.

The IGRA tests cannot prove that latent TB infections will progress into active TB until the patient begins to show symptoms. Better tools to predict who will go on to develop active and potentially infectious TB are being actively pursued. The investigators found that 96 inmates tested positive for TB via the TST test, but only 31 of these inmates were confirmed as true latent TB infection when using the IGRA test.

Wendy L.Wobeser, MD, the study’s lead author said, “It is fairly uncommon that latent TB will reactivate, with only about a 10% chance. That said, given the crowding in corrections facilities, the mass exposure of inmates to TB could be disastrous. It is such a slow disease progression that it is hard for us to say with certainty who will actually go on to develop TB. I hope that this test will eventually be used in corrections and is able to reduce people who might otherwise be treated unnecessarily for latent TB.”

Ilan Schwartz, MD, a coauthor of the study said, “What I found surprising was just how much discordance there was between the TST and IGRA tests. Historically, all of those who tested TB-positive by the TST test would have been subjected to 12 months of drug treatments that can have considerable side effects.”

Related Links:

Queen’s University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.